Biomarker staging of liver fibrosis in hepatitis C was cost effective, but so was initiating treatment without testing.

Lamarre, D. et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426, 186–189 (2003).

Jensen, D. M. & Ascione, A. Future directions in therapy for chronic hepatitis C. Antivir. Ther. 13 (Suppl. 1), 31–36 (2008). Vertex. Vertex Reports 52% SVR 12 Rate for a 24-week Telaprevir ...